UGI CORP /PA/ Quarterly Retained Earnings (Accumulated Deficit) in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Ugi Corp /Pa/ quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q1 2010 to Q3 2024.
  • Ugi Corp /Pa/ Retained Earnings (Accumulated Deficit) for the quarter ending September 30, 2024 was $2.98B, a 1.62% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $2.98B -$49M -1.62% Sep 30, 2024 10-K 2024-11-26
Q2 2024 $3.33B +$357M +12% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $3.46B -$382M -9.94% Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $3.04B -$766M -20.1% Dec 31, 2023 10-Q 2024-02-01
Q3 2023 $3.03B -$1.81B -37.5% Sep 30, 2023 10-K 2024-11-26
Q2 2023 $2.97B -$1.7B -36.4% Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $3.84B -$915M -19.2% Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $3.81B -$100M -2.56% Dec 31, 2022 10-Q 2024-02-01
Q3 2022 $4.84B +$760M +18.6% Sep 30, 2022 10-K 2023-11-29
Q2 2022 $4.67B +$1.05B +28.8% Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $4.76B +$1.2B +33.7% Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $3.91B +$769M +24.5% Dec 31, 2021 10-Q 2023-02-02
Q3 2021 $4.08B +$1.17B +40.3% Sep 30, 2021 10-K 2022-11-21
Q2 2021 $3.63B +$659M +22.2% Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $3.56B +$604M +20.5% Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $3.14B +$341M +12.2% Dec 31, 2020 10-Q 2022-02-03
Q3 2020 $2.91B +$255M +9.61% Sep 30, 2020 10-K 2021-11-19
Q2 2020 $2.97B +$209M +7.56% Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $2.95B +$135M +4.78% Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $2.8B +$177M +6.76% Dec 31, 2019 10-Q 2021-02-04
Q3 2019 $2.65B +$42.3M +1.62% Sep 30, 2019 10-K 2020-11-20
Q2 2019 $2.76B +$124M +4.7% Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $2.82B +$162M +6.08% Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $2.62B +$192M +7.88% Dec 31, 2018 10-Q 2020-02-06
Q3 2018 $2.61B +$504M +23.9% Sep 30, 2018 10-K 2019-11-26
Q2 2018 $2.64B +$485M +22.6% Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $2.66B +$442M +20% Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $2.43B +$394M +19.4% Dec 31, 2017 10-Q 2019-02-07
Q3 2017 $2.11B +$273M +14.9% Sep 30, 2017 8-K 2019-05-06
Q2 2017 $2.15B +$226M +11.7% Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $2.21B +$308M +16.2% Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $2.04B +$323M +18.9% Dec 31, 2016 10-Q 2018-02-06
Q3 2016 $1.83B +$197M +12% Sep 30, 2016 10-K 2017-11-21
Q2 2016 $1.93B +$241M +14.3% Jun 30, 2016 10-Q 2017-08-04
Q1 2016 $1.91B +$191M +11.1% Mar 31, 2016 10-Q 2017-05-05
Q4 2015 $1.71B +$206M +13.7% Dec 31, 2015 10-Q 2017-02-03
Q3 2015 $1.64B +$128M +8.45% Sep 30, 2015 10-K 2016-11-22
Q2 2015 $1.69B +$119M +7.57% Jun 30, 2015 10-Q 2016-08-05
Q1 2015 $1.72B +$135M +8.55% Mar 31, 2015 10-Q 2016-05-06
Q4 2014 $1.51B +$108M +7.73% Dec 31, 2014 10-Q 2016-02-05
Q3 2014 $1.51B +$201M +15.4% Sep 30, 2014 10-K 2015-11-30
Q2 2014 $1.57B +$212M +15.6% Jun 30, 2014 10-Q 2015-08-07
Q1 2014 $1.58B +$202M +14.7% Mar 31, 2014 10-Q 2015-05-08
Q4 2013 $1.4B +$170M +13.8% Dec 31, 2013 10-Q 2015-02-06
Q3 2013 $1.31B +$152M +13.2% Sep 30, 2013 10-K 2014-11-28
Q2 2013 $1.35B +$144M +11.9% Jun 30, 2013 10-Q 2014-08-07
Q1 2013 $1.38B +$130M +10.4% Mar 31, 2013 10-Q 2014-05-09
Q4 2012 $1.23B +$84.3M +7.37% Dec 31, 2012 10-Q 2014-02-07
Q3 2012 $1.16B +$70.2M +6.47% Sep 30, 2012 10-K 2013-12-16
Q2 2012 $1.21B +$73.9M +6.5% Jun 30, 2012 10-Q 2013-08-02
Q1 2012 $1.25B +$74.4M +6.34% Mar 31, 2012 10-Q 2013-05-15
Q4 2011 $1.14B +$91.6M +8.71% Dec 31, 2011 10-Q 2013-02-08
Q3 2011 $1.09B +$119M +12.3% Sep 30, 2011 10-K 2012-11-21
Q2 2011 $1.14B +$145M +14.6% Jun 30, 2011 10-Q 2012-08-08
Q1 2011 $1.17B +$157M +15.5% Mar 31, 2011 10-Q 2012-05-04
Q4 2010 $1.05B Dec 31, 2010 10-Q 2012-02-03
Q3 2010 $967M Sep 30, 2010 10-K 2011-11-21
Q2 2010 $992M Jun 30, 2010 10-Q 2011-08-05
Q1 2010 $1.02B Mar 31, 2010 10-Q 2011-05-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.